All News

ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types, while emphasizing the need for prospective clinical research.

With no new kidney-protective therapies approved in T1D for over 3 decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how stigma from health care providers or frontline staff impacts patient willingness to seek or continue treatment.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss common myths and misconceptions surrounding antidepressants, antipsychotics, and medications for addiction treatment in congregate care settings.

Phase 3 SARC041 data show that abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.

The trial met both dual primary end points of pathologic complete response and metastasis-free survival.

SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.

At ASCO 2026, GLORA investigators report on lisaftoclax as an addition to BTK inhibitors to deepen responses and delay progression in high-risk CLL/SLL.

Seven-year CROWN trial update shows lorlatinib delivers durable progression-free survival and strong brain control in ALK-positive NSCLC.

APP-led benign hematology consult programs helped community oncology practices significantly reduce time to first appointment while strengthening interdisciplinary collaboration with pharmacists and physicians.

DREAMM-9 data show belantamab mafodotin in TI NDMM delivers high responses, with longer dosing improving eye safety and quality of life.

Enfortumab vedotin combination delivers lasting complete responses in la/mUC.

ASCO 2026 data show perioperative enfortumab vedotin plus pembrolizumab boosts EFS, OS, and pCR in cisplatin-eligible MIBC.

ASCO 2026: Glofitamab monotherapy shows durable remissions in relapsed mantle cell lymphoma after BTKi, with manageable CRS.

At ASCO 2026, CHRYSALIS-2 data show amivantamab plus lazertinib extends survival in atypical EGFR-mutated NSCLC, reshaping first-line care.

Emerging evidence links GLP-1 receptor agonists to improved breast cancer outcomes and the growing importance of metabolic health in survivorship care.

New findings suggest that differences in immune reconstitution kinetics may drive variations in graft-versus-host disease incidence, infection risk, and overall survival.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

This interview discusses emerging immunotherapy trends at the 2026 ASCO Annual Meeting, including cancer vaccines, cell-based therapies, ADCs, and AI-driven immune profiling tools poised to reshape oncology care.

Hidden payer site-of-care restrictions delay specialty infusions, driving administrative burden and patient harm—and show why transparent criteria and better coordination matter.

Subgroup data show ofatumumab sharply cuts relapses, MRI lesions, and neurodamage markers in highly active relapsing MS vs teriflunomide.

Genetic analysis links low vitamin D and earlier menarche to higher AQP4-IgG NMOSD risk, reshaping prevention and sparking calls for diverse studies.

Phase 3 FENhance trial data show CNS-penetrant BTK inhibitor fenebrutinib cuts relapses and MRI lesions in relapsing MS.

New data show ublituximab boosts MS quality of life fast and may start in 1 infusion for relapsing multiple sclerosis.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Jacci Bainbridge, PharmD, FCCP, Professor Vice Chair for Research and Scholarship, Neurology Pharmacy, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking long-term MS therapy, de-escalation, biomarkers and the future of care for MS.

New data show cladribine tablets deliver strong relapse control and reassuring safety in older adults with relapsing multiple sclerosis, including 65 years and older.